Pharmaceutical News

RSS

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Early anticlotting therapy offers benefits for moderately ill patients with Covid-19

COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death.

13 Jul 2021

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

The Global Antibiotic Research and Development Partnership, the Clinton Health Access Initiative and Shionogi & Co., Ltd today announced a Memorandum of Understanding to accelerate access, including in low- and middle-income countries, to the antibiotic cefiderocol for bacterial infections in patients with limited treatment options.

13 Jul 2021

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

The Food and Drug Administration's approval in June of a drug purporting to slow the progression of Alzheimer's disease was widely celebrated, but it also touched off alarms.

12 Jul 2021

What is behind the inconsistent results of COVID-19 clinical trials?

“Most clinical studies of antiviral drugs for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have failed to observe a statistically significant effect, which may be due to poor designs of clinical trials.”

12 Jul 2021

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

The drugmaker Pfizer, one of the companies behind the Pfizer-BioNTech vaccine, or BNT162b2, awaits the green light to develop a COVID-19 booster shot that can protect against emerging variants. Pfizer’s COVID-19 vaccine has been shown to be 95% effective in an ongoing large-scale clinical trial against the original SARS-CoV-2 strain.

11 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Doctors weigh pros and cons of prescribing hot-button Alzheimer’s drug

As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer's disease approved in 18 years, patients want to know: "Will this medication help me — and how much?"

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

LGM Pharma launches standalone analytical services for drug developers and manufacturers

LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.

From LGM Pharma 8 Jul 2021

New analysis finds muscle relaxant drugs to be largely ineffective for low back pain

Muscle relaxant drugs are largely ineffective for low back pain, despite being widely prescribed for this condition, suggests an analysis of the latest evidence published by The BMJ today.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

Study: Opioid prescribing preferences, practices among surgical residents and faculty differ

Opioid prescribing preferences and practices among surgical residents and faculty differ, according to a new study published in the journal Surgery.

8 Jul 2021

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.

7 Jul 2021

Doctors advise against off-label use of new Alzheimer's medicine for cerebral amyloid angiopathy

A novel therapy recently approved by the U.S. Food and Drug Administration for patients with Alzheimer's disease amid considerable controversy should not be prescribed by physicians off-label for cerebral amyloid angiopathy (CAA), a similar cerebrovascular condition, according to Steven Greenberg, MD, PhD, director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital (MGH) and president of the International Cerebral Amyloid Angiopathy Association (ICAAA).

7 Jul 2021

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

A group of researchers recently discussed their findings that a group of plant flavonols and dihydroflavonols exhibit antiviral efficacy against both SARS-CoV-2 and HCoV-229E.

6 Jul 2021

Investigation reveals considerable added benefit of remdesivir for moderately ill COVID-19 patients

Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation.

6 Jul 2021

Anti-rheumatic drug combinations could reduce the risk of heart attack and strokes

New research evaluating the drugs commonly used by rheumatoid arthritis patients suggests two combinations could reduce the risk of heart attack and strokes.

6 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Pharmaceutical News

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Early anticlotting therapy offers benefits for moderately ill patients with Covid-19

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

What is behind the inconsistent results of COVID-19 clinical trials?

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Doctors weigh pros and cons of prescribing hot-button Alzheimer’s drug

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

LGM Pharma launches standalone analytical services for drug developers and manufacturers

New analysis finds muscle relaxant drugs to be largely ineffective for low back pain

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Study: Opioid prescribing preferences, practices among surgical residents and faculty differ

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Doctors advise against off-label use of new Alzheimer's medicine for cerebral amyloid angiopathy

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

Investigation reveals considerable added benefit of remdesivir for moderately ill COVID-19 patients

Anti-rheumatic drug combinations could reduce the risk of heart attack and strokes

Antibiotic clofoctol shows potential against SARS-CoV-2

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News